Vorinostat (suberoylanilide hydroxamic acid, SAHA) is an HDAC inhibitor that is currently FDA approved for the treatment of recurrent cutaneous T-cell lymphoma (CTCL) and is under investigation for other (i.e., hematologic) malignancies. The gene discussed is HDAC9; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.